Author(s): Undas A, CeliskaLwenhoff M, Kaczor M, Musial J, Undas A, CeliskaLwenhoff M, Kaczor M, Musial J, Undas A, CeliskaLwenhoff M, Kaczor M, Musial J, Undas A, CeliskaLwenhoff M, Kaczor M, Musial J
Abstract Share this page
Abstract Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, statins, have been demonstrated to reduce cardiovascular morbidity and mortality in patients with a wide range of cholesterol levels. Numerous cholesterol-independent effects of statins that may limit atherosclerosis are probably related to inhibition of the geranylgeranylation of GTP-binding intracellular signaling proteins and involve: improved vasoreactivity, mostly through increased NO bioavailability; decreased expression of proinflammatory cytokines (interleukin-6, interleukin-1 beta, tumor necrosis factor alpha), C-reactive protein, chemokines, matrix metalloproteinases, and tissue factor with the subsequent inhibition of thrombin generation; reduced platelet activity; increased thrombomodulin expression; enhanced fibrinolysis, regulation of angiogenesis and immunomodulation. However, the clinical relevance of multiple protective effects induced by statins has not been clarified yet.
This article was published in Thromb Haemost
and referenced in Journal of Nutritional Disorders & Therapy